4552 On Other Exchanges
Symbol
Exchange
4552 is not on other exchanges.

jcr pharmaceuticals co ltd (4552) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JCR PHARMACEUTICALS CO LTD (4552)

Related News

No related news articles were found.

jcr pharmaceuticals co ltd (4552) Related Businessweek News

No Related Businessweek News Found

jcr pharmaceuticals co ltd (4552) Details

JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, marketing, and sale of biopharmaceutical products and regenerative medicines primarily in Japan. Its product pipeline includes Follicle stimulating hormone, which is in Phase I/II clinical trials for the treatment of infertility; Alpha-galactosidase A that is in Phase II/III clinical trials to treat fabry disease; Iduronate-2-sulfatase, which is in the clinical trial in preparation stage for hunter syndrome; and Darbopoetin Alfa that is in Phase I clinical trials to treat renal anemia. The company’s preclinical product pipeline comprises Glucocerebrosidase for gaucher disease, BBB-Penetrating Iduronate-2-sulfatase for the treatment of hunter syndrome, and Long-acting Somatropin for growth disorder treatment. It also develops human mesenchymal stem cells for the treatment of graft-versus-host disease. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is headquartered in Ashiya, Japan.

431 Employees
Last Reported Date: 06/22/16
Founded in 1975

jcr pharmaceuticals co ltd (4552) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jcr pharmaceuticals co ltd
JCR Pharmaceuticals Co., Ltd. to Report Q3, 2017 Results on Jan 26, 2017

JCR Pharmaceuticals Co., Ltd. announced that they will report Q3, 2017 results on Jan 26, 2017

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2017 Results on Oct 27, 2016

JCR Pharmaceuticals Co., Ltd. announced that they will report Q2, 2017 results on Oct 27, 2016

Kissei Pharmaceutical Co., Ltd. and JCR Pharmaceuticals Co., Ltd. Initiate Phase III Renal Anemia Trial

Kissei Pharmaceutical Co., Ltd. and JCR Pharmaceuticals Co., Ltd. have initiated a Phase III clinical trial of JR-131, a biosimilar for a long-acting erythropoiesis-stimulating agent, darbepoetin alfa for the treatment of renal anemia. The equivalence of pharmacokinetics has been verified and the safety has been confirmed in the Phase I clinical trial, thus a Phase III clinical trial is to be initiated. The companies both aim to contribute to the improvement of medical treatment for renal anemia through development of the economically efficient JR-131 and provision of this new treatment option, by leveraging JCR's know-how and expertise in biopharmaceutical manufacturing that meets the global quality standards.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4552 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4552.
View Industry Companies
 

Industry Analysis

4552

Industry Average

Valuation 4552 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JCR PHARMACEUTICALS CO LTD, please visit www.jcrpharm.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.